Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and partnership deals have shown clearly that the space is of interest. (MobiHealthNews is helping to put on two pharma-related events at the mHealth Summit next week -- be sure to join us if you'll be in...
A WellPoint health plan in Florida, called Amerigroup Florida, announced that it will offer Asthmapolis' FDA-cleared mobile health device and service to its members with asthma.
Asthmapolis' device is a sensor that sits atop (most) inhalers used by patients who have asthma or COPD. The sensor transmits data to a companion app on the user’s mobile phone every time the inhaler is used. The app can...
